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Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood
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the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine
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Background-—Elevated resting heart rate (HR) and low systolic blood pressure (SBP) are related to poor outcomes in heart failure
(HF). The association between visit-to-visit variation in SBP and HR and risk in HF is unknown.
Methods and Results-—In Systolic Heart Failure Treatment with the If inhibitor ivabradine Trial (SHIFT) patients, we evaluated
relationships between mean HR, mean SBP, and visit-to-visit variations (coefﬁcient of variation [CV]=SD/mean9100%) in SBP and
HR (SBP-CV and HR-CV, respectively) and primary composite endpoint (cardiovascular mortality or HF hospitalization), its
components, all-cause mortality, and all-cause hospitalization. High HR and low SBP were closely associated with risk for primary
endpoint, all-cause mortality, and HF hospitalization. The highest number of primary endpoint events occurred in the highest HR
tertile (38.8% vs 16.4% lowest tertile; P<0.001). For HR-CV, patients at highest risk were those in the lowest tertile. Patients in the
lowest thirds of mean SBP and SBP-CV had the highest risk. The combination of high HR and low HR-CV had an additive deleterious
effect on risk, as did that of low SBP and low SBP-CV. Ivabradine reduced mean HR and increased HR-CV, and increased SBP and
SBP-CV slightly.
Conclusions-—Beyond high HR and low SBP, low HR-CV and low SBP-CV are predictors of cardiovascular outcomes with additive
effects on risk in HF, but with an unknown effect size. Beyond HR reduction, ivabradine increases HR-CV. Low visit-to-visit variation
of HR and SBP might signal risk of cardiovascular outcomes in systolic HF.
Clinical Trial Registration-—URL: http://www.isrctn.com/. Unique identiﬁer: ISRCTN70429960. ( J Am Heart Assoc. 2016;5:
e002160 doi: 10.1161/JAHA.115.002160)
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I n patients with chronic heart failure (HF), low(<120 mm Hg) systolic blood pressure (SBP)1–3 and
elevated (>70 bpm) heart rate (HR)4,5 are associated with
poor outcome. In patients with hypertension, it has been
shown that high visit-to-visit blood pressure variation predicts
cardiovascular risk,6 which is independent of other cardio-
vascular risk factors, including SBP at baseline.7 Increased
variation of SBP might be partially related to abnormal
autonomic function8,9 or arterial stiffness9 and is associated
with carotid atherosclerosis,10 silent cerebral injury, stroke,11
and cognitive decline.12 The mechanisms and the potential
value for outcome prediction of visit-to-visit HR variation (HR-
CV) are not known. It is also currently unknown whether visit-
to-visit variation of SBP (SBP-CV) is associated with outcomes
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in HF, where patients usually present with low blood
pressure.1–3 In the Systolic Heart failure treatment with the
If inhibitor ivabradine Trial (SHIFT), it has been shown that in
patients with systolic HF (ejection fraction ≤35%) and HR
≥70 beats per minute (bpm)13 or ≥75 bpm,14 selective HR
reduction with ivabradine reduced cardiovascular death or HF
hospitalization. This analysis aimed to rigorously characterize
the association of SBP and diastolic blood pressure (DBP) and
their visit-to-visit variation (CV [coefﬁcient of variation]) as
well as HR and HR-CV with cardiovascular outcomes in the
SHIFT trial.
Methods
Studied Patients and Procedures
The primary objectives, the protocol and the outcomes of
SHIFT have been previously described in detail.3,13–15 In brief,
SHIFT was a randomized, double-blind, placebo-controlled
outcomes trial in patients with sinus rhythm and chronic
moderate-to-severe HF. Patients had left ventricular systolic
dysfunction with an ejection fraction ≤35% and an HR
≥70 bpm in sinus rhythm. In total, 6505 patients in 37
countries (677 medical centers) were randomly assigned to
either placebo or ivabradine 5 mg BID, which could be
uptitrated to 7.5 mg BID or downtitrated to 2.5 mg BID
depending on tolerability and HR. HR was measured by a 12-
lead electrocardiogram on 2 consecutive visits before
randomization, at baseline, and at every follow-up visit in
the study. The primary endpoint was the composite of
cardiovascular death or hospitalization for HF. Secondary
endpoints included the individual components of the primary
endpoint, HF death, all-cause hospitalization, and all-cause
death. All outcomes were adjudicated by an endpoint
validation committee according to predeﬁned criteria.13,15
Blood pressure was measured at every visit preferably on the
same arm after at least 5 minutes of rest with patients in a
seated position. The study was reviewed by an institutional
review board, and all patients gave written consent.
Visit-to-visit variation of systolic and diastolic blood
pressure (SBP-CV and DBP-CV) has previously shown to be
reproducible and applicable in clinical practice.16 The average
of several measurements over time has been shown to
provide more-precise information on the risk for cardiovas-
cular events in a population of patients after myocardial
infarction (MI) or stroke.17 Mean BP and mean HR were
calculated using measurements at each postbaseline visit.
Visit-to-visit variation of BP and HR were calculated as a CV,
that is, the ratio of SD to the mean (CV=SD/mean9100%).
Measurements from all postbaseline visits were included.
Altogether, 72.4 visits (range, 2–12) were available for the
whole group (placebo: 6.82.5; range, 2–12; ivabradine:
7.12.2; range, 2–12). Data were analyzed for all visits and in
a sensitivity analysis for patients with a minimum of 3 visits.
Statistical Analysis
Descriptive statistics are presented as meanSD for contin-
uous variables and as numbers and percentages for categor-
ical variables. Distributions of patients according to mean HR,
HR-CV, mean SBP, and SBP-CV were divided into thirds,
allowing statistical evaluations of the cohort with adequate
group sizes. Statistics in the thirds were tested for differences
using ANOVA for continuous data and chi-square for
categorical data. Variation in risk across the thirds of means
and CVs was tested in a Cox proportional hazard model
adjusted for beta-blocker use, New York Heart Association
(NYHA) class, left ventricular ejection fraction (LVEF),
ischemic heart failure, age, estimated glomerular ﬁltration
rate (eGFR), body mass index, and history of diabetes and,
where applicable, adjusted for baseline HR, baseline SBP,
mean HR, mean SBP, and mean DBP. Adjusted hazard ratios
were calculated with reference to the lowest risk group or the
middle risk group, as appropriate. Pearson correlations were
calculated for the mean, CV, and SDs of the HR, SBP, and
DBP. Differences in mean values of parameters between the
ivabradine and placebo values were tested using 2-sample t
tests. Differences in median values of these parameters were
compared using a Kruskal–Wallis test. SAS software (version
9.2; SAS Institute Inc., Cary, NC) was used for all analyses.
Results
Correlation of Mean SDs and CVs
CV was chosen as a measure of variation because it is more
independent of the mean than SD. The correlation between
HR-CV and HR mean was not signiﬁcant (r=0.017; P=0.35) in
the placebo population. It was slightly more pronounced, but
still weak (r=0.108; P<0.0001), in patients treated with
ivabradine. In contrast, the association of mean HR to SD of
HR was r=0.27 (P<0.0001) in patients on placebo and r=0.36
(P<0.0001) in patients on ivabradine. Similar results were
obtained with blood pressure: mean SBP was related to SD of
SBP with placebo (r=0.27; P<0.0001) and with ivabradine
(r=0.32; P<0.0001). The association was weaker for SBP-CV
with placebo (r=0.05; P=0.0123) and with ivabradine (r=0.10;
P<0.0001). Therefore, CV was chosen for the analysis instead
of SD, because it was less dependent on the mean. There was
a weak correlation between mean SBP and mean HR (0.054;
P=0.0034) with placebo, but none with ivabradine (r=0.014;
P=0.45), whereas the correlation between SBP-CV and HR-CV
was moderate with placebo (r=0.09; P<0.0001) and ivabra-
dine (r=0.11; P<0.0001).
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Demographics and Clinical Characteristics
Demographic data and clinical characteristics are presented for
in-trial mean HR and in-trial mean SBP in patients assigned
either to placebo or ivabradine (Tables 1 through 4). Table 1
shows baseline characteristics of placebo patients according
to thirds of mean HR. There were some statistical differences,
some of which might be relevant. Elderly people tend to have
lower HR, whereas patients with lower left ventricular function
and current smokers have higher HR. There were differences
according to use of beta-blocker, with patients on beta-
blockers and, in particular, those on higher doses having lower
HR. Similar results were observed in the ivabradine population
(Table 2). Table 3 summarizes baseline characteristics accord-
ing to thirds of mean SBP. Patients with low SBP appear to be
younger and also have lower DBP. Higher beta-blocker dose
was more frequently observed in patients with higher SBP.
Similar results were obtained in the ivabradine group (Table 4).
Analyses were done on group sizes of between 961 and 988.
We report on the data of all visits available. When patients with
1, 3, or more visits were evaluated in a sensitivity analysis,
similar results were obtained (not shown).
Clinical Outcomes According to HR and HR-CV
Figure 1 shows the association of the primary endpoint
(cardiovascular death or heart failure hospitalization; Fig-
ure 1A), HF hospitalization (Figure 1B), and all-cause mortality
(Figure 1C) with mean HR in patients on placebo (left) and in
patients on ivabradine (right). There was a clear association
between increased cardiovascular outcomes and higher mean
HR in both the placebo group (left) and the ivabradine group
(right). This was true not only for the primary endpoint and HF
hospitalization, but also for all-cause mortality. The associa-
tions were similar in the ivabradine group (right panels), which
had lower mean HR as a whole (data not shown), for these 3
endpoints.
Slightly different results were observed with HR-CV. The
middle third had the lowest nominal risk (Figure 2), with a
signiﬁcant increase of risk in the third with the lowest HR-CV.
For the primary endpoint, the lowest third of HR-CV was
associated with the highest risk on placebo (Figure 2A, left).
This effect was attenuated with ivabradine (Figure 2A, right).
Similar results were obtained for HF hospitalization (Fig-
ure 2B) and all-cause mortality (Figure 2C).
Figure 3 summarizes adjusted hazard ratios for HF
outcomes according to mean HR and HR-CV. There was a
step-wise increase in the risk for the primary endpoint,
cardiovascular mortality, HF hospitalization, all-cause mortal-
ity, and all-cause hospitalization with increased HR in the
placebo group (Figure 3A) and the ivabradine group (data not
shown). For HR-CV, the middle tertiles of the placebo group
(Figure 3B) and ivabradine group (data not shown) had the
lowest risk. Furthermore, HR-CV, at all stages, appeared to be
higher in the ivabradine group than in the placebo group (data
not shown).
Interaction of HR and HR-CV
In order to test whether there was an interaction betweenmean
HR and HR-CV on risk of HF outcomes, outcomes were
analyzed according to thirds of HR and HR-CV. The risk for the
primary endpoint (Figure 4A), cardiovascular mortality (Fig-
ure 4B), and HF hospitalization (Figure 4C) was greatest in
patients with the lowest third of HR-CV and highest third of
mean HR; risk was lowest patients in the middle third of HR-CV
and with the lowest mean HR. These associations were more
pronounced in patients on placebo (left) than in those on
ivabradine (right), where risk was generally lower. Importantly,
the HR-CV values did not differ in the different tertiles of mean
HR. The values were on placebo: HR mean tertile 1: HR-CV,
0.093; tertile 2: HR-CV, 0.095; and tertile 3: HR-CV, 0.099; and
on ivabradine: HR mean tertile 1: HR-CV, 0.102; tertile 2: HR-
CV, 0.115; and tertile 3: HR-CV, 0.118, respectively.
Clinical Outcomes According to SBP and SBP-CV
Figure 5 summarizes the association between third of mean
SBP and risk of the primary endpoint (Figure 5A), HF
hospitalization (Figure 5B) and all-cause mortality (Figure 5C)
in the placebo (left) and ivabradine (right) groups. The lowest
third of SBP (ie, <117 mm Hg) was predictive of the highest
outcome rates, whereas risk appeared broadly similar for
patients in the middle and upper thirds. For patients on
placebo (left) and ivabradine (right), log-rank P was <0.001.
Figure 6 summarizes the effect of SBP-CV on the risk of heart
failure outcomes. Interestingly, the lowest third of SBP-CV
was predictive for the greatest risk of the primary outcome
(Figure 6A), HF hospitalization (Figure 6B) and all-cause
mortality (Figure 6C) in the placebo group (left) and
ivabradine group (right). For all associations, log-rank
P<0.001, except for all-cause mortality with placebo
(P=0.004). Figure 7 summarizes adjusted hazard ratios for
HF outcomes according to mean SBP and SBP-CV. The third
with the lowest SBP-CV had the lowest risk, and this was used
as the reference hazard ratio (HR=1.0). The associations were
similar for placebo (Figure 7B) and ivabradine (not shown). As
with mean HR and HR-CV, there was an interaction between
SBP and SBP-CV (Figure 8). Patients with the highest risk for
primary endpoint (Figure 8A), cardiovascular mortality (Fig-
ure 8B), and HF hospitalization (Figure 8C) whether on
placebo (left) or ivabradine (right) were those in the group
with the lowest third of mean SBP and lowest third of SBP-CV.
Again, as with mean HR and HR-CV, SBP-CV values were
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Table 1. Placebo Population: Baseline Characteristics by In-Trial HR Mean Tertiles
Heart Rate
P Value
≤70 bpm
(N=978)
>70 and ≤78.7 bpm
(N=988)
>78.7 bpm
(N=964)
Age (y), mean (SD) 61.8 (10.6) 60.3 (11.2) 58.4 (12.2) <0.001
Male (%) 747 (76.4) 757 (76.6) 752 (78.0) 0.655
Caucasian vs non-Caucasian (%) 880 (90.0) 862 (87.2) 837 (86.8) 0.066
Current smokers (%) 123 (12.6) 173 (17.5) 213 (22.1) <0.001
Body mass index (kg/m2), mean (SD) 27.7 (4.4) 27.9 (5.0) 28.1 (5.5) 0.144
Resting heart rate (bpm), mean (SD) 75.0 (5.2) 77.7 (6.9) 87.2 (10.9) <0.001
Systolic blood pressure (mm Hg), mean (SD) 121.7 (15.5) 121.1 (15.5) 120.7 (16.3) 0.328
Diastolic blood pressure (mm Hg), mean (SD) 75.3 (8.9) 75.3 (9.5) 76.1 (9.7) 0.088
LVEF (%), mean (SD) 29.7 (4.8) 28.9 (5.4) 28.3 (5.2) <0.001
eGFR (mL/min per 1.73 m2), mean (SD) 73.5 (22.4) 75.7 (23.0) 76.9 (23.1) 0.004
Serum creatinine (lmol/L), mean (SD) 97.2 (25.6) 96.0 (27.6) 94.9 (24.5) 0.149
Haemoglobin (g/L), mean (SD) 140.8 (14.5) 141.8 (14.6) 143.9 (15.6) <0.001
NYHA Class III/IV vs Class II (%) 458 (46.8) 478 (48.4) 556 (57.7) <0.001
Ischemic heart failure (%) 718 (73.4) 655 (66.3) 591 (61.3) <0.001
History of MI (%) 611 (62.5) 546 (55.3) 475 (49.3) <0.001
History of hypertension (%) 669 (68.4) 633 (64.1) 605 (62.8) 0.024
History of diabetes (%) 258 (26.4) 311 (31.5) 333 (34.5) <0.001
History of stroke (%) 82 (8.4) 93 (9.4) 87 (9.0) 0.722
History of COPD (%) 68 (7.0) 86 (8.7) 165 (17.1) <0.001
Coronary artery disease (%) 768 (78.5) 701 (71.0) 642 (66.6) <0.001
Beta-blocker at randomization (%) 916 (93.7) 908 (91.9) 807 (83.7) <0.001
Beta-blocker dose: no BB (%) 62 (6.5) 80 (8.2) 157 (16.4) <0.001
Beta-blocker dose: <25% (%) 122 (12.7) 123 (12.7) 136 (14.2)
Beta-blocker dose: 25%; 50% (%) 260 (27.1) 263 (27.1) 229 (24.0)
Beta-blocker dose: 50%; 100% (%) 273 (28.5) 261 (26.9) 237 (24.8)
Beta-blocker dose: ≥100% (%) 241 (25.2) 244 (25.1) 196 (20.5)
Selective beta-blocker at randomization (%) 546 (55.8) 510 (51.6) 417 (43.3) <0.001
Beta-2 agonists at randomization (%) 10 (1.0) 23 (2.3) 54 (5.6) <0.001
Drugs for obstructive airway disease at randomization (%) 43 (4.4) 73 (7.4) 142 (14.7) <0.001
Adrenergics, inhalants at randomization (%) 23 (2.4) 46 (4.7) 86 (8.9) <0.001
Adrenergics and other drugs for obstructive airway
disease at randomization (%)
15 (1.5) 29 (2.9) 46 (4.8) <0.001
ACE inhibitor at randomization (%) 784 (80.2) 783 (79.3) 722 (74.9) 0.011
Diuretic at randomization (%) 785 (80.3) 802 (81.2) 820 (85.1) 0.014
ARB at randomization (%) 128 (13.1) 147 (14.9) 147 (15.2) 0.348
Calcium-channel blocker at randomization (%) 79 (8.1) 87 (8.8) 64 (6.6) 0.195
Antialdosterone at randomization (%) 548 (56.0) 576 (58.3) 617 (64.0) 0.001
Device (%) 28 (2.9) 48 (4.9) 42 (4.4) 0.065
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, beta blocker; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association.
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Table 2. Ivabradine Population: Baseline Characteristics by In-Trial HR Mean Tertiles
Heart Rate
P Value
≤60.4 bpm
(N=965)
>60.4 and ≤68.6 bpm
(N=966)
>68.6 bpm
(N=961)
Age (y), mean (SD) 62.1 (10.6) 61.3 (11.3) 59.0 (11.6) <0.001
Male (%) 695 (72.0) 751 (77.7) 741 (77.1) 0.006
Caucasian vs non-Caucasian (%) 870 (90.2) 854 (88.4%) 833 (86.7) 0.059
Current smokers (%) 122 (12.6) 164 (17.0) 209 (21.7) <0.001
Body mass index (kg/m2), mean (SD) 27.9 (4.6) 28.1 (5.1) 28.1 (5.6) 0.623
Resting heart rate (bpm), mean (SD) 75.5 (6.0) 78.2 (7.5) 85.3 (11.0) <0.001
Systolic blood pressure (mm Hg), mean (SD) 121.7 (15.4) 121.9 (15.8) 122.0 (17.0) 0.906
Diastolic blood pressure (mm Hg), mean (SD) 75.1 (9.3) 75.5 (9.7) 76.6 (9.9) 0.003
LVEF (%), mean (SD) 29.4 (5.0) 29.1 (5.1) 28.4 (5.4) <0.001
eGFR (mL/min per 1.73 m2), mean (SD) 72.8 (21.7) 75.1 (23.0) 76.8 (23.7) <0.001
Serum creatinine (lmol/L), mean (SD) 97.0 (26.2) 95.8 (25.6) 95.5 (27.3) 0.438
Hemoglobin (g/L), mean (SD) 140.0 (14.2) 141.4 (14.9) 142.4 (15.3) 0.002
NYHA Class III/IV vs Class II (%) 450 (46.6) 479 (49.6) 531 (55.3) <0.001
Ischemic heart failure (%) 694 (71.9) 671 (69.5) 600 (62.4) <0.001
History of MI (%) 575 (59.6) 558 (57.8) 478 (49.7) <0.001
History of hypertension (%) 666 (69.0) 641 (66.4) 615 (64.0) 0.066
History of diabetes (%) 234 (24.2) 282 (29.2) 349 (36.3) <0.001
History of stroke (%) 68 (7.0) 63 (6.5) 58 (6.0) 0.668
History of COPD (%) 66 (6.8) 121 (12.5) 122 (12.7) <0.001
Coronary artery disease (%) 729 (75.5) 713 (73.8) 660 (68.7) 0.002
Beta-blocker at randomization (%) 903 (93.6) 876 (90.7) 817 (85.0) <0.001
Beta-blocker dose: no BB (%) 62 (6.6) 90 (9.4) 144 (15.3) <0.001
Beta-blocker dose: <25% (%) 130 (13.7) 138 (14.4) 156 (16.5)
Beta-blocker dose: 25%; 50% (%) 229 (24.2) 235 (24.6) 236 (25.0)
Beta-blocker dose: 50%; 100% (%) 285 (30.1) 256 (26.8) 213 (22.6)
Beta-blocker dose: ≥100% (%) 240 (25.4) 238 (24.9) 194 (20.6)
Selective beta-blocker at randomization (%) 478 (49.5) 463 (47.9) 467 (48.6) 0.778
Beta-2 agonists at randomization (%) 9 (0.9) 22 (2.3) 28 (2.9) 0.007
Drugs for obstructive airway disease at randomization (%) 55 (5.7) 78 (8.1) 113 (11.8) <0.001
Adrenergics, inhalants at randomization (%) 31 (3.2) 42 (4.3) 61 (6.3) 0.004
Adrenergics and other drugs for obstructive airway
disease at randomization (%)
23 (2.4) 24 (2.5) 42 (4.4) 0.018
ACE inhibitor at randomization (%) 769 (79.7) 794 (82.2) 740 (77.0) 0.018
Diuretic at randomization (%) 795 (82.4) 793 (82.1) 835 (86.9) 0.006
ARB at randomization (%) 159 (16.5) 116 (12.0) 123 (12.8) 0.010
Calcium-channel blocker at randomization (%) 96 (9.9) 80 (8.3) 75 (7.8) 0.214
Antialdosterone at randomization (%) 561 (58.1) 615 (63.7) 600 (62.4) 0.032
Device (%) 27 (2.8) 32 (3.3) 30 (3.1) 0.803
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, beta blocker; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association.
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Table 3. Placebo Population: Baseline Characteristics by In-Trial Systolic Blood Pressure Mean Tertiles
SBP
P Value
≤117
mm Hg
(N=984)
>117 and
≤128.7 mm Hg
(N=974)
>128.7
mm Hg
(N=977)
Age (y), mean (SD) 58.1 (12.3) 60.5 (11.0) 61.9 (10.8) <0.001
Male (%) 764 (77.6) 766 (78.6) 730 (74.7) 0.101
Caucasian vs non-Caucasian (%) 805 (81.8) 872 (89.5) 907 (92.8) <0.001
Current smokers (%) 168 (17.1) 179 (18.4) 163 (16.7) 0.586
Body mass index (kg/m2), mean (SD) 26.5 (4.7) 27.8 (4.6) 29.4 (5.2) <0.001
Resting heart rate (bpm), mean (SD) 80.9 (10.7) 79.6 (9.0) 79.2 (8.8) <0.001
Systolic blood pressure (mm Hg), mean (SD) 108.8 (11.9) 121.3 (11.2) 133.6 (13.0) <0.001
Diastolic blood pressure (mm Hg), mean (SD) 70.1 (8.4) 76.0 (8.0) 80.7 (8.5) <0.001
LVEF (%), mean (SD) 27.6 (5.4) 29.2 (5.2) 30.1 (4.5) <0.001
eGFR (mL/min per 1.73 m2), mean (SD) 76.8 (25.1) 75.3 (21.9) 73.9 (21.4) 0.024
Serum creatinine (lmol/L), mean (SD) 95.7 (25.4) 96.1 (25.9) 96.4 (26.5) 0.847
Hemoglobin (g/L), mean (SD) 140.9 (14.9) 141.7 (14.4) 143.9 (15.4) <0.001
NYHA Class III/IV vs Class II (%) 529 (53.8) 494 (50.7) 473 (48.5) 0.063
Ischemic heart failure (%) 602 (61.2) 675 (69.3) 690 (70.6) <0.001
History of MI (%) 529 (53.8) 567 (58.2) 538 (55.1) 0.125
History of hypertension (%) 430 (43.7) 657 (67.5) 824 (84.3) <0.001
History of diabetes (%) 236 (24.0) 315 (32.3) 352 (36.0) <0.001
History of stroke (%) 81 (8.2) 94 (9.7) 88 (9.0) 0.545
History of COPD (%) 107 (10.9) 104 (10.7) 109 (11.2) 0.943
Coronary artery disease (%) 638 (64.8) 719 (73.8) 757 (77.5) <0.001
Beta-blocker at randomization (%) 872 (88.6) 873 (89.6) 890 (91.1) 0.191
Beta-blocker dose: no BB (%) 112 (11.5) 101 (10.5) 87 (9.1) <0.001
Beta-blocker dose: <25% (%) 171 (17.5) 120 (12.5) 90 (9.4)
Beta-blocker dose: 25%; 50% (%) 282 (28.9) 233 (24.3) 238 (24.9)
Beta-blocker dose: 50%; 100% (%) 239 (24.5) 261 (27.2) 273 (28.6)
Beta-blocker dose: ≥100% (%) 171 (17.5) 245 (25.5) 266 (27.9)
Selective beta-blocker at randomization (%) 431 (43.8) 492 (50.5) 552 (56.5) <0.001
Beta-2 agonists at randomization (%) 27 (2.7) 29 (3.0) 31 (3.2) 0.854
Drugs for obstructive airway disease at randomization (%) 89 (9.0) 83 (8.5) 86 (8.8) 0.920
Adrenergics, inhalants at randomization (%) 53 (5.4) 53 (5.4) 49 (5.0) 0.900
Adrenergics and other drugs for obstructive airway
disease at rand (%)
33 (3.4) 32 (3.3) 25 (2.6) 0.528
ACE inhibitor at randomization (%) 736 (74.8) 764 (78.4) 793 (81.2) 0.003
Diuretic at randomization (%) 831 (84.5) 781 (80.2) 799 (81.8) 0.045
ARB at randomization (%) 142 (14.4) 137 (14.1) 143 (14.6) 0.936
Calcium-channel blocker at randomization (%) 30 (3.0) 59 (6.1) 141 (14.4) <0.001
Antialdosterone at randomization (%) 703 (71.4) 607 (62.3) 434 (44.4) <0.001
Device (%) 71 (7.2) 28 (2.9) 19 (1.9) <0.001
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, beta blocker; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association.
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Table 4. Ivabradine Population: Baseline Characteristics by In-Trial Systolic Blood Pressure Mean Tertiles
SBP
P Value
≤119.2
mm Hg
(N=971)
>119.2 and
≤130.6 mm Hg
(N=964)
>130.6
mm Hg
(N=967)
Age (y), mean (SD) 58.4 (11.9) 61.7 (10.9) 62.4 (10.5) <0.001
Male (%) 753 (77.5) 743 (77.1) 700 (72.4) 0.014
Caucasian vs non-Caucasian (%) 795 (81.9) 868 (90.0) 903 (93.4) <0.001
Current smokers (%) 166 (17.1) 157 (16.3) 174 (18.0) 0.609
Body mass index (kg/m2), mean (SD) 26.6 (4.8) 28.1 (4.9) 29.5 (5.2) <0.001
Resting heart rate (bpm), mean (SD) 79.9 (9.5) 79.3 (9.3) 79.8 (9.3) 0.271
Systolic blood pressure (mm Hg), mean (SD) 108.8 (11.9) 122.2 (11.0) 134.6 (13.3) <0.001
Diastolic blood pressure (mm Hg), mean (SD) 70.1 (8.6) 76.1 (7.9) 81.0 (9.1) <0.001
LVEF (%), mean (SD) 28.0 (5.5) 29.1 (5.1) 29.8 (4.7) <0.001
eGFR (mL/min per 1.73 m2), mean (SD) 76.0 (23.7) 75.2 (22.5) 73.5 (22.3) 0.060
Serum creatinine (lmol/L), mean (SD) 96.6 (26.8) 95.4 (25.0) 96.5 (27.3) 0.534
Hemoglobin (g/L), mean (SD) 140.3 (14.9) 141.1 (14.4) 142.6 (15.1) 0.003
NYHA Class III/IV vs Class II (%) 495 (51.0) 484 (50.3) 486 (50.3) 0.935
Ischemic heart failure (%) 618 (63.6) 684 (71.0) 669 (69.2) 0.002
History of MI (%) 543 (55.9) 565 (58.6) 508 (52.5) 0.027
History of hypertension (%) 468 (48.2) 652 (67.6) 806 (83.4) <0.001
History of diabetes (%) 230 (23.7) 282 (29.3) 354 (36.6) <0.001
History of stroke (%) 65 (6.7) 51 (5.3) 73 (7.5) 0.127
History of COPD (%) 98 (10.1) 93 (9.6) 121 (12.5) 0.091
Coronary artery disease (%) 665 (68.5) 722 (74.9) 722 (74.7) 0.002
Beta-blocker at randomization (%) 865 (89.1) 874 (90.7) 866 (89.6) 0.500
Beta-blocker dose: no BB (%) 106 (11.0) 90 (9.4) 101 (10.8) <0.001
Beta-blocker dose: <25% (%) 188 (19.5) 133 (14.0) 104 (11.1)
Beta-blocker dose: 25%; 50% (%) 250 (26.0) 234 (24.6) 218 (23.2)
Beta-blocker dose: 50%; 100% (%) 247 (25.6) 242 (25.4) 266 (28.3)
Beta-blocker dose: ≥100% (%) 172 (17.9) 254 (26.7) 250 (26.6)
Selective beta-blocker at randomization (%) 409 (42.1) 483 (50.1) 520 (53.8) <0.001
Beta-2 agonists at randomization (%) 15 (1.5) 23 (2.4) 21 (2.2) 0.395
Drugs for obstructive airway disease at randomization (%) 74 (7.6) 69 (7.2) 105 (10.9) 0.007
Adrenergics, inhalants at randomization (%) 38 (3.9) 44 (4.6) 53 (5.5) 0.258
Adrenergics and other drugs for obstructive
airway disease at randomization (%)
25 (2.6) 26 (2.7) 39 (4.0) 0.122
ACE inhibitor at randomization (%) 758 (78.1) 776 (80.5) 778 (80.5) 0.313
Diuretic at randomization (%) 837 (86.2) 783 (81.2) 811 (83.9) 0.012
ARB at randomization (%) 122 (12.6) 125 (13.0) 152 (15.7) 0.090
Calcium-channel blocker at randomization (%) 28 (2.9) 82 (8.5) 142 (14.7) <0.001
Antialdosterone at randomization (%) 700 (72.1) 580 (60.2) 503 (52.0) <0.001
Device (%) 52 (5.4) 24 (2.5) 13 (1.3) <0.001
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, beta blocker; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; SBP, systolic blood pressure.
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similar in the mean SBP tertiles (placebo: SBP mean tertile 1:
SBP-CV, 0.074; tertile 2: SBP-CV, 0.072; and tertile 3: SBP-
CV, 0.073; ivabradine: SBP mean tertile 1: SBP-CV, 0.075;
tertile 2: SBP-CV, 0.073; tertile 3: SBP-CV, 0.078).
Clinical Outcome According to DBP and DBP-CV
We also determined the effect of mean DBP and DBP-CV
on the risk of HF outcomes. As with SBP, patients with the
Figure 1. Kaplan–Meier event curves for the primary endpoint (cardiovascular death or heart failure
hospitalization) (A), heart failure hospitalization (B), and all-cause mortality (C) in placebo (left) and
ivabradine (right) patients according to thirds of mean rate (heart rate mean) tertiles. Cox regression P
values are given. HR CV indicates coefﬁcient of heart rate variation.
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lowest third of DBP had the highest risk (Figure 9), whether
they were taking placebo (left) or ivabradine (right).
Patients with the lowest third of DBP-CV also had the
highest risk (Figure 10). Adjusted hazard ratios for HF
outcomes according to mean DBP and DBP-CV are
summarized in Figure 11. Interaction between mean DBP
and DBP-CV was similar to that between mean SBP and
SBP-CV (Figure 12).
Figure 2. Kaplan–Meier event curves for the primary endpoint (cardiovascular death or heart failure
hospitalization) (A), heart failure hospitalization (B), and all-cause mortality (C) in placebo (left) and
ivabradine (right) patients according to thirds of coefﬁcient of heart rate variation (HR CV). Cox regression P
values are given.
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Effect of Ivabradine on HR-CV and SBP-CV
Whereas the effect of ivabradine on outcome reduction is
known to be related to reduction in HR,5,13 its effects on HR-
CV and SBP-CV were unknown. We tested the difference
between placebo- and ivabradine-treated patients according
to median or mean values of HR, SBP, DBP, HR-CV, SBP-CV,
and DBP-CV (Table 5). Mean HR values were signiﬁcantly
reduced by ivabradine compared to placebo. Whereas mean
SBP increased slightly with ivabradine, no signiﬁcant differ-
ences were detected in mean DBP. Interestingly, treatment
with ivabradine increased HR-CV and led to small absolute
increases in SBP-CV and DBP-CV.
Discussion
In this analysis, we have shown that the individual visit-to-visit
variations in HR and SBP together with mean HR and mean
SBP were associated with cardiovascular outcomes in a
population of patients with systolic HF on contemporary
Figure 3. Adjusted hazard ratios show the association in placebo patients between thirds of heart rate (A,
HR mean, left) and heart rate coefﬁcient of variation (B, HR CV, right) and the primary endpoint
(cardiovascular death or hospitalization for heart failure), cardiovascular mortality (CV mortality), heart
failure hospitalization (HF hospitalization), all-cause mortality, and all-cause hospitalization.
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treatments. A high HR and a low SBP were associated with
the primary composite endpoint of the SHIFT trial, cardiovas-
cular mortality or HF hospitalization, as well as its individual
components, all-cause mortality, and all-cause hospitalization.
Patients with the lowest third of HR-CV had the highest risk of
outcomes. The effects of mean HR and HR-CV on risk were
additive. Low mean SBP and low SBP-CV were also related to
poor outcomes. Interestingly, in addition to its HR-reducing
effect, ivabradine restored HR-CV and slightly increased SBP-
CV.
Previous studies have shown that high resting HR4,5 and
low SBP1–3 are associated with increased cardiovascular
A Primary Endpoint
Placebo Ivabradine
Interaction of HR mean and HR CV
B Cardiovascular Mortality
Placebo Ivabradine
% %
% %
C Heart Failure Hospitalization
Placebo Ivabradine
% %
Figure 4. Interaction between mean heart rate (HR mean) and heart rate coefﬁcient of variation (HR CV)
for the primary endpoint (cardiovascular death or heart failure hospitalization) (A), cardiovascular mortality
(B), and heart failure hospitalization (C) in placebo (left) and ivabradine (right) patients.
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mortality and early rehospitalization for worsening HF. These
studies are mainly based on a single measurement of HR and
SBP. By using the mean of multiple measurements, our
ﬁndings agree with these previous studies, showing that risk
of the primary endpoint of SHIFT was related to tertiles of
baseline HR. After HR was reduced by ivabradine, there was a
reduction in HF death, HF hospitalization, and a nonsigniﬁcant
reduction of cardiovascular death in the overall SHIFT
population.14,15 We also showed that the association of HR
to risk was sustained when HR remained high, despite
treatment with ivabradine. This is in line with the ﬁnding that
in patients with low HR on ivabradine, there was a strong risk
Figure 5. Kaplan–Meier event curves for the primary endpoint (cardiovascular death or heart failure
hospitalization) (A), heart failure hospitalization (B), and all-cause mortality (C) in placebo (left) and
ivabradine (right) patients according to thirds of mean systolic blood pressure (SBP mean).
DOI: 10.1161/JAHA.115.002160 Journal of the American Heart Association 12
Variation of SBP and HR in Heart Failure B€ohm et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 10, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
reduction, whereas there was a high residual risk in patients
whose HR did not decline on treatment.5 Adjusting risk by the
number of heart beats reduced neutralized risk reduction by
ivabradine in SHIFT.5 The novelty of this report is that low
visit-to-visit variation of SBP and HR are also associated with
risk in this population, who usually present with low or normal
SBP,1–3 but high HR.4,5
Here, we investigated the mean HR and SBP values over all
visits during the observation periods. It has been shown that
in patients at higher cardiovascular risk, mean SBP and HR
Figure 6. Kaplan–Meier event curves for the primary endpoint (cardiovascular death or heart failure
hospitalization) (A), heart failure hospitalization (B), and all-cause mortality (C) in placebo (left) and
ivabradine (right) patients according to thirds of coefﬁcient of variation of systolic blood pressure (SBP CV).
Cox regression P values are given.
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measured at several visits long term is more predictive of
outcomes than HR and SBP measured just at baseline.17 In
hypertensive individuals, in addition to long-term mean SBP,
variation of SBP is predictive of, and also independently
associated with, risk.8,9 Mechanistically, it was suggested that
this variation is associated with episodic peaks and, thus high
variance of SBP might be important in the short run for
triggering of vascular events.18 In the HF population of SHIFT,
patients with the lowest SBP variation had the highest
subsequent risk. Patients with low SBP and low SBP-CV were
at the highest risk, providing evidence that HF patients with
persistently low BP have the highest risk. Again, this is
opposite to what is observed in hypertension. Interestingly,
here, we show that not only low SBP-CV, but also low HR-CV
is associated with outcome. Patients in the middle third of HR-
CV nominally had the lowest risk. Risk was particularly high in
HF patients with low HR-CV and high mean HR. Clinically, it is
important for physicians to note that patients presenting
constantly with high HR and low SBP at several visits over
time are at a particularly high risk of death or hospitalization.
Figure 7. Adjusted hazard ratios show the association in placebo patients between thirds of systolic
blood pressure (A, SBP mean, left) and systolic blood pressure coefﬁcient of variation (B, SBP CV, right) and
the primary endpoint (cardiovascular death or hospitalization for heart failure), cardiovascular mortality (CV
mortality), heart failure hospitalization (HF hospitalization), all-cause mortality, and all-cause hospitalization.
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Associations of mean SBP and SBP-CV with risk are opposite
in HF and hypertension (“inverse epidemiology”). Similar
patterns were also observed for DBP, which is also associated
with risk in hypertensive individuals.19
Mechanistically, high intraindividual variation of blood
pressure was suggested to be related to nonadherence to
treatment with antihypertensive drugs.20 However, unlike in
hypertension trials,21–23 here, low SBP variation was associ-
A Primary Endpoint
Placebo Ivabradine
Interaction of SBP mean and SBP CV
B Cardiovascular Mortality
Placebo Ivabradine
% %
% %
C Heart Failure Hospitalization
Placebo Ivabradine
% %
Figure 8. Interaction between mean systolic blood pressure (SBP mean) and systolic blood pressure
coefﬁcient of variation (SBP CV) for the primary endpoint (cardiovascular death or heart failure
hospitalization) (A), cardiovascular mortality (B), and heart failure hospitalization (C) in placebo (left) and
ivabradine (right) patients.
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ated with increased risk. This indicates that, as with mean
SBP, the SBP-CV risk relation in HF is opposite to that in
hypertension. Nonadherence to the study medication, ivabra-
dine, and to placebo amounted to 21% and 19%, respectively.
However, we did not capture adherence to accompanying HF
cotreatment, all affecting at least blood pressure. Thus, we
cannot say whether adherence changes to those drugs
contribute to this ﬁnding. Because the association occurs on
ivabradine and on placebo, nonadherence does not likely play
a role. Thus, eventually, autonomic dysfunction related to
DBP Mean - Placebo DBP Mean - Ivabradine
A Primary Endpoint
B Heart Failure Hospitalization
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Figure 9. Kaplan–Meier event curves for the primary endpoint (cardiovascular death or heart failure
hospitalization) (A), heart failure hospitalization (B), and all-cause mortality (C) in placebo (left) and
ivabradine (right) patients according to third of mean diastolic blood pressure (DBP). Cox regression P
values are given.
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persistent high HR or severely impaired cardiac output
associated with low SBP resulting in a small variation might
also play a role in higher event rates. Beyond hypertension,
the effect of visit-to-visit variation of BP was shown to be
predictive in subjects with diabetes, which might also be
inﬂuenced by the degree of autonomic dysfunction.24 Inter-
estingly, the association between SBP as well as SBP-CV to
risk was not, or minimally, changed by ivabradine. In contrast,
ivabradine increased HR-CV. It has previously been shown
that several antihypertensive drugs differentially affect
DBP CV - Placebo DBP CV - Ivabradine
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C All-Cause Mortality
0
5
10
15
20
25
30
35
40
0 1 2 3
Pe
rc
en
ta
ge
 w
ith
 e
ve
nt
0
5
10
15
20
25
30
35
40
0 1 2 3
Pe
rc
en
ta
ge
 w
ith
 e
ve
nt
0
5
10
15
20
25
30
35
40
0 1 2 3
Pe
rc
en
ta
ge
 w
ith
 e
ve
nt
0
5
10
15
20
25
30
35
40
0 1 2 3
Pe
rc
en
ta
ge
 w
ith
 e
ve
nt
Lower third
Middle third
Upper third
0
5
10
15
20
25
30
35
40
0 1 2 3
Pe
rc
en
ta
ge
 w
ith
 e
ve
nt
0
5
10
15
20
25
30
35
40
0 1 2 3
Pe
rc
en
ta
ge
 w
ith
 e
ve
nt
Years since randomization Years since randomization
p<0.001 p<0.001
p<0.001 p<0.001
p<0.001 p<0.001
Figure 10. Kaplan–Meier event curves for the primary endpoint (cardiovascular death or heart failure
hospitalization) (A), heart failure hospitalization (B), and all-cause mortality (C) in placebo (left) and
ivabradine (right) patients according to third of diastolic blood pressure coefﬁcient of variation (DBP CV).
Cox regression P values are given.
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SBP-CV, which has been shown to be related to their effects
of reducing stroke.22 In SHIFT,14,15 the effect of ivabradine is
attributed to HR reduction, given that risk reduction is
neutralized when the effects were adjusted for the reduction
of HR by ivabradine.5 Here, we have documented that HR-CV
was increased by ivabradine. Therefore, in patients with low
HR-CV, restoration of HR variation by ivabradine might add
another contributing mechanism, or at least indicator, for the
risk-reducing effect of the If inhibitor beyond HR reduction
itself. However, this analysis is hypothesis generating because
we cannot say how much this ﬁnding could contribute to risk
reduction by ivabradine. It could also be the consequence of
improvement of HF with a reduction of neuroendocrine
dysfunction after HR reduction by ivabradine.
Limitations
Some limitations of the present analysis should be acknowl-
edged. This was a post-hoc exploratory analysis. Individuals
were not subjected to randomization. Nevertheless, the large
Figure 11. Association in placebo patients between thirds of diastolic blood pressure (A, DBP mean, left)
and diastolic blood pressure coefﬁcient of variation (B, DBP CV, right) and the primary endpoint
(cardiovascular death or hospitalization for heart failure), cardiovascular mortality (CV mortality), heart
failure hospitalization (HF hospitalization), all-cause mortality, and all-cause hospitalization.
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study population and the rigorous capture of HR and SBP
data provide the statistical power to allow reliable analysis
of the relationships to risk. In addition, these ﬁndings might
have clinical importance because they show physicians that
low SBP variation and low HR variation over a series of visits
might provide important clinical information on future
outcomes in HF patients. It has to be emphasized that
these data apply to HF with systolic dysfunction, whereas in
the HF population with preserved ejection fraction, no data
are available.
A Primary Endpoint
Placebo Ivabradine
Interaction of DBP mean and DBP CV
B Cardiovascular Mortality
Placebo Ivabradine
% %
% %
C Heart Failure Hospitalization
Placebo Ivabradine
% %
Figure 12. Interaction between mean heart rate (HR mean) and heart rate coefﬁcient of variation (HR
CV) for the primary endpoint (cardiovascular death or heart failure hospitalization) (A), cardiovascular
mortality (B), and heart failure hospitalization (C) in placebo (left) and on ivabradine (right) patients.
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Conclusions
The results of this post-hoc analysis in an HF population with
systolic dysfunction treated with recommended drugs according
tocontemporary guidelineshave shown that beyondHRandSBP,
variations in these clinical parameters over time are predictive of
risk. Physicians should therefore note that patients with low
variation of HR and SBP might be at particular risk and require
adjustment of treatment and careful follow-up. In HF, inverse
epidemiology occurs: High SBP-CV is associated with higher risk
in hypertension,6–11 but lower risk in systolic HF. Finally,
ivabradine restored HR variation, which could be a marker for,
or even contribute to, risk reduction beyond HR reduction.
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Table 5. Effect of Ivabradine on Values (Mean Values and
Their Variations in Heart Rate, Systolic Blood Pressure, and
Diastolic Blood Pressure
Placebo
(Mean)
Ivabradine
(Mean) P Value*
Heart rate 75.4 65.7 <0.0001
Systolic blood pressure 122.6 125.0 <0.0001
Diastolic blood pressure 76.2 75.8 0.0619
Heart rate CV 0.095 0.112 <0.0001
Systolic blood pressure CV 0.073 0.075 0.0072
Diastolic blood pressure CV 0.079 0.081 0.0640
CV indicates coefﬁcient of variation.
*t test was used to compare differences between mean values.
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